Cure8 research brief
Patients and clinicians want blood or noninvasive tests that reflect what is seen on colonoscopy. This study identifies XCL1 as a blood biomarker candidate associated with endoscopic activity in Crohn's disease, though it did not outperform fecal calprotectin.
Clinicians who manage Crohn's disease, researchers studying IBD biomarkers or immune pathways, and patients interested in noninvasive disease monitoring.
This study tested whether the chemokine XCL1 in blood is linked to endoscopic inflammation in Crohn's disease. Researchers analyzed PBMC transcriptomes, checked XCL1 in intestinal biopsies, and measured serum XCL1 by ELISA in 125 patients with Crohn's disease and 40 controls, then compared levels across SES-CD endoscopic activity groups.
The investigators found XCL1 was upregulated in PBMCs and increased in inflamed intestinal mucosa; serum XCL1 levels varied by SES-CD group and were associated with endoscopic activity but performed worse than fecal calprotectin (FC). Authors describe XCL1 as a potential exploratory adjunctive serum marker that needs further validation.
This report is based on the article abstract and provided full-text extract from the journal; it summarizes the study design and the authors' stated conclusions without implying clinical recommendations.
Single-center observational biomarker study with comparative analyses; authors note XCL1's performance was inferior to fecal calprotectin and that further validation is required. The content depth is an abstract/summary of the published study.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
